Hyperbaric Oxygen as an Adjunct in Zygomycosis: Randomized Controlled Trial in a Murine Model

ABSTRACT Zygomycosis was induced by injecting CD-1 mice with 5 mg of intraperitoneal deferoxamine and then 106 CFU of intravenous and intrasinus Rhizopus arrhizus. The addition of hyperbaric oxygen (2.0 atm absolute twice daily) to amphotericin B did not improve survival over that achieved with amphotericin B and placebo air treatments.

[1]  M. Ghannoum,et al.  Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models , 1998, Antimicrobial Agents and Chemotherapy.

[2]  R. Markert,et al.  Survival factors in rhino-orbital-cerebral mucormycosis. , 1994, Survey of ophthalmology.

[3]  Eric P. Kindwall,et al.  Hyperbaric Medicine Practice , 1994 .

[4]  J. Griswold,et al.  Intracranial complications of mucormycosis: An experimental model and clinical review , 1992, The Laryngoscope.

[5]  A. Fenves,et al.  Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  A. Espinel-Ingroff,et al.  Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi , 1991, Journal of clinical microbiology.

[7]  T. K. Hunt,et al.  Oxygen and wound healing. , 1990, Clinics in plastic surgery.

[8]  T. G. Mitchell,et al.  Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. , 1988, Reviews of infectious diseases.

[9]  Davis Cp,et al.  Combined effects of hyperbaric oxygen and antifungal agents on the growth of Candida albicans. , 1987 .

[10]  T. Gudewicz,et al.  Combined effects of hyperbaric oxygen and antifungal agents on the growth of Candida albicans. , 1987, Aviation, space, and environmental medicine.

[11]  G. Medoff,et al.  Amphotericin B-induced oxidative damage and killing of Candida albicans. , 1986, The Journal of infectious diseases.

[12]  R. Diamond,et al.  Cerebral mucormycosis in diabetic mice after intrasinus challenge , 1984, Infection and immunity.

[13]  A. Blitzer,et al.  Patient survival factors in paranasal sinus mucormycosis , 1980, The Laryngoscope.